Bronchopulmonary Dysplasia - A Pipeline Analysis Report| Technavio
May. 14, 2018
LONDON--(BUSINESS WIRE)--May 14, 2018-- presents its latest pipeline analysis report on the market. The report offers an exhaustive analysis of the pipeline molecules under investigation within the defined data collection period to treat bronchopulmonary dysplasia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514005756/en/
Technavio has published a new pipeline analysis report on the global bronchopulmonary dysplasia market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
The report will also provide an analysis of the various factors that are expected to play an essential role in the growth of the market during the forecast period, including regulatory framework, drug development strategies, recruitment strategies, and key companies.
Bronchopulmonary dysplasia - market at a glance
Bronchopulmonary dysplasia is a chronic respiratory infection, which regularly happens in low birth weight or premature babies or newborn babies with intense respiratory distress syndrome who have provided with supplement oxygen or kept in a breathing machine (machine ventilation) for a long time. can also occur in older infants who experience abnormal lung development or in infants who have an infection before birth (antenatal infection) or placental abnormalities such as pre-eclampsia.
According to a senior analyst at Technavio for , “Some premature infants get affected with respiratory distress syndrome, which is a breathing disorder, immediately after birth. It is characterized by rapid, shallow breathing and leads to the need for oxygen and respiratory support in the first few days of life. The infants who are affected by bronchopulmonary dysplasia may also feel shortness of breath, flaring of nostrils while inhaling, a chronic cough, and staining of the skin because of low levels of oxygen in the blood.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Bronchopulmonary dysplasia - segmentation analysis
This market research report segments the market based on therapies employed that includes monotherapy, RoA (intratracheal, intravenous, inhaled, and oral), therapeutic modalities (small molecules and biomolecule), targets for drugs under development (IGF-1 and IGFBP-3, SCGB1A1, thioredoxin, CXCR1/2, and unspecified), MoA (protein replacement, cell replacement, IGF-1 receptor, thioredoxin mimetic, CXCR1/2 antagonist, and undisclosed), and recruitment status (not yet recruiting, completed, active not recruiting, and unspecified).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, all the molecules that are being invested are monotherapy.
Intratracheal refers to the introduction of drugs into the trachea. It is an alternative to inhalation. In the current pipeline, 49% of the total therapeutics are being developed for intratracheal administration.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180514005756/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES BABY/MATERNITY RESEARCH CONSUMER SCIENCE GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/14/2018 09:40 AM/DISC: 05/14/2018 09:40 AM